A Combinatorial Approach to Wound Healing for Protein, Gene and Cell Therapeutics

描述(由申请人提供)：我们提出了一个14个月的、里程碑式的、基准的研究计划，延长了P20中心专注于生物疗法开发的父母拨款。这项研究最初将由加州大学圣迭戈分校新招聘的6个学术研究和技术职位执行。通过与圣地亚哥当地生物技术社区的伙伴关系，将在药物发现、药物筛选和药物开发方面发展持续和新的就业机会。具体地说，我们将：(1)表达我们在亲代基金(P20GM078421)中鉴定的新发现的重组神经肽蛋白。将合成类似物来识别功能结构域，并测试激动剂和拮抗剂。(2)研制高特异性的单抗，建立检测其在疾病中的作用的定量ELISA法。(3)通过创建基因敲除和条件性敲除的模型来评估创面修复的临床前模型，以(A)建立其生理相关性，(B)作为药物发现的模型，以及(C)协助将候选药物转化为药物先导。(4)通过分子克隆鉴定其受体，建立药物发现的检测方法。(5)定位启动子，建立荧光素酶报告基因转基因小鼠。(6)将所产生的技术转移给私营部门以供进一步发展。资金将建立在母项目成功的基础上，扩大其范围，为实验室带来新的基本技能，加快科学研究的节奏，并通过雇用更多员工、增加现有兼职员工的工作时间以及签订合同获得更多所需技能，从而创造(和保留)大量就业机会。这项资助的计划将创造6个新的全职职位，使我们能够维持目前正在进行的2个研究职位，随着成功的结果，我们预计将通过向私营生物技术部门转让技术，在药物开发研究职位上额外创造5-15个新职位。 相关性：本研究项目描述了5个具有里程碑意义的具体目标，这些目标将创建、测试和验证一种新的伤口愈合疗法。它将立即创造6个全职职位，如果成功，它的第六个AIM将通过向私营部门转让技术创造5-15个新的就业机会。

DESCRIPTION (provided by applicant): We propose an 14 month, milestone-driven, benchmarked research plan that extends a parent P20 Center grant focusing on bio-therapeutics development. The research will initially be executed by 6 newly hired academic research and technical positions at UCSD. Sustained and new employment in drug discovery, drug screening and drug development will be developed by partnerships with the San Diego's local biotechnology community. Specifically we will: (1) express a newly discovered recombinant neuropeptide protein that we identified in the parent grant (P20 GM078421). Analogs will be synthesized to identify functional domains and test agonists and antagonists. (2) develop high specificity monoclonal antibodies and create a quantitative ELISA assay to measure its role in disease. (3) evaluate preclinical models of wound repair by creating models of gene knock down and conditional knock outs to (a) establish its physiological relevance, (b) serve as models for drug discovery and (c) assist in converting the drug candidate to a drug lead. (4) identify its receptor by molecular cloning to establish an assay for drug discovery. (5) map the promoter to create a luciferase reporter transgenic mouse. (6) transfer technology generated to the private sector for further development. Funding will build on the success of the parent project, extend its scope, bring new fundamental skills to the laboratory, accelerate the tempo of scientific research and allow for significant job creation (and retention) by enabling hiring of additional staff, increasing hours of current part-time staff, and contracting for additional needed skills. The funded program will create 6 new full time positions, enable us to sustain 2 ongoing current research positions and with a successful outcome, we anticipate would generate an additional 5-15 new jobs in drug development research positions by technology transfer to the private biotechnology sector. Relevance: This research project describes 5 milestone and bench-marked specific AIMs that will create, test and validate a new therapeutic for wound healing. It will immediately create 6 full time positions and, if successful, its 6th AIM will create 5-15 new jobs by technology transfer to the private sector.